Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - PLx Pharma Inc. | v463352_ex31-1.htm |
| EX-32.1 - EXHIBIT 32.1 - PLx Pharma Inc. | v463352_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - PLx Pharma Inc. | v463352_ex31-2.htm |
| 10-Q - FORM 10-Q - PLx Pharma Inc. | v463352_10q.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Dipexium Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert G. Shawah, Chief Accounting Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| Dipexium Pharmaceuticals, Inc. | ||
| By: | /s/ Robert G. Shawah | |
| Robert G. Shawah | ||
| Chief Accounting Officer and Treasurer | ||
| (Principal Financial and Accounting Officer) | ||
April 17, 2017